Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Research & Development (2016 - 2026)

Summit Therapeutics filings provide 13 years of Research & Development readings, the most recent being $132.6 million for Q1 2026.

  • Quarterly Research & Development rose 158.69% to $132.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $619.0 million through Mar 2026, up 261.65% year-over-year, with the annual reading at $537.7 million for FY2025, 256.6% up from the prior year.
  • Research & Development hit $132.6 million in Q1 2026 for Summit Therapeutics, down from $147.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $208.0 million in Q2 2025 and bottomed at $5.4 million in Q4 2022.
  • Average Research & Development over 5 years is $54.9 million, with a median of $30.8 million recorded in 2024.
  • The largest annual shift saw Research & Development tumbled 76.69% in 2022 before it skyrocketed 575.44% in 2025.
  • Summit Therapeutics' Research & Development stood at $5.4 million in 2022, then skyrocketed by 360.71% to $24.8 million in 2023, then soared by 107.07% to $51.4 million in 2024, then soared by 186.66% to $147.3 million in 2025, then fell by 9.96% to $132.6 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Research & Development are $132.6 million (Q1 2026), $147.3 million (Q4 2025), and $131.1 million (Q3 2025).